Delineate
Winter 2025Agents for Accelerated Clinical Trial Design
About Company
Delineate is building AI agents to design better clinical trials faster. This is a $10B dollar market, where saving even 1 day along the process is equal to $1-5M in revenue potential. We process existing clinical trial research into specialized datasets saving scientists months of effort. Delineate is working with two of the largest pharmaceutical companies. With one of our customers, we are helping them get to the next phase of trials faster by creating the largest dataset on a drug class ever constructed.
Active Founders
Co-founder at Delineate. Previously she was an MIT PhD Candidate in Biological Engineering and worked at Pfizer and AstraZeneca where she focused on applying AI to modeling and simulation for drug development optimization.
